Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876915 · ClinicalTrials.gov registry record · Phase 3
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
A Phase 3 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
NCT00876915: Clinical Trial Phase 3 study, sponsored by University of Rochester.
NCT00876915 is a Phase 3 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 218 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00876915, a Phase 3 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
Study Summary
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening. The purpose of this study is to determine if a daily injection of a blood-thinner, dalteparin, for 12 weeks can safely and effectively reduce the frequency of blood clots. Dalteparin is currently approved for prevention of blood clots following surgery and in hospitalized patients but not specifically for cancer outpatients.
Primary Outcome
The percentage of patients who developed a Venous thromboembolism were recorded within 12 weeks following randomization including all adjudicated occurrences of symptomatic DVT, PE and upper extremity thrombus as well as all asymptomatic DVT and PE detected by lower extremity ultrasonography and chest CT.
Interventions
- DRUG dalteparin injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Why NCT00876915 stopped before completion
NCT00876915 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which dalteparin injection is the first listed.
NCT00876915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00876915 about?
NCT00876915 is a clinical study titled "A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients". Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening. The purpose of this study is to determine if a daily injection of a blood-thinner, daltepar...
What is the current status of trial NCT00876915?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2009-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00876915?
The interventions under investigation include: dalteparin injection (DRUG).
Who is sponsoring clinical trial NCT00876915?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00876915's enrollment target sits among peer trials
218 1331st of 2000 higher than 669 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia